Literature DB >> 9744577

Decrease in thymidylate kinase activity in peripheral blood mononuclear cells from HIV-infected individuals.

B Jacobsson1, S Britton, Y Törnevik, S Eriksson.   

Abstract

Nucleosides and nucleoside analogs are anabolised to their triphosphates by intracellular kinases. The anti-HIV analogue zidovudine (AZT) is phosphorylated by cytosolic thymidine kinase 1 (TK1), thymidylate kinase (dTMPK), and nucleoside diphosphate kinase. It is known that dTMPK is one of the rate-limiting steps in the activation of zidovudine. The activities of TK1, dTMPK, and deoxycytidine kinase (dCK) were determined in extracts of in vitro activated peripheral blood mononuclear cells from HIV-infected patients and healthy noninfected individuals. dTMPK activity was 10-fold lower and TK1 activity was five-fold lower in extracts from infected as compared to uninfected persons. Deoxycytidine kinase activities in the extracts from both groups were very similar. Differences in in vitro activation, as determined by flow cytometry, of the peripheral lymphocytes were not responsible for the decreased TK1 and dTMPK activities. A reduced level of intracellular azido-dideoxythymidinetriphosphate in activated mononuclear cells from HIV-infected patients was also observed. The low levels of TK1 and dTMPK in lymphocytes from HIV-infected patients may be related to the anergy phenomenon observed as a result of HIV infection. This effect should also be considered in the development of new anti-HIV drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9744577     DOI: 10.1016/s0006-2952(98)00032-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  Mechanisms of substrate selectivity for Bacillus anthracis thymidylate kinase.

Authors:  Cecilia Carnrot; Liya Wang; Dimitri Topalis; Staffan Eriksson
Journal:  Protein Sci       Date:  2008-06-03       Impact factor: 6.725

2.  Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo.

Authors:  P G Hoggard; S D Sales; D Phiboonbanakit; J Lloyd; B A Maher; S H Khoo; E Wilkins; P Carey; C A Hart; D J Back
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive thai patients and healthy volunteers.

Authors:  Y Wattanagoon; K Na Bangchang; P G Hoggard; S H Khoo; S E Gibbons; D Phiboonbhanakit; J Karbwang; D J Back
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

4.  Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine.

Authors:  Joseph E Rower; Amie Meditz; Edward M Gardner; Kenneth Lichtenstein; Julie Predhomme; Lane R Bushman; Brandon Klein; Jia-Hua Zheng; Samantha Mawhinney; Peter L Anderson
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

5.  The crystal structure of human adenylate kinase 6: An adenylate kinase localized to the cell nucleus.

Authors:  Hui Ren; Liya Wang; Matthew Bennett; Yuhe Liang; Xiaofeng Zheng; Fei Lu; Lanfen Li; Jie Nan; Ming Luo; Staffan Eriksson; Chuanmao Zhang; Xiao-Dong Su
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-03       Impact factor: 11.205

6.  Human inter-individual variability in metabolism and genotoxic response to zidovudine.

Authors:  Ofelia A Olivero; Jessica M Ming; Shreyasi Das; Irma L Vazquez; Diana L Richardson; Ainsley Weston; Miriam C Poirier
Journal:  Toxicol Appl Pharmacol       Date:  2007-12-14       Impact factor: 4.219

7.  Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.

Authors:  Selwyn J Hurwitz; Raymond F Schinazi
Journal:  Drug Discov Today Technol       Date:  2012

8.  Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.

Authors:  Selwyn J Hurwitz; Ghazia Asif; Nancy M Kivel; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

9.  Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages.

Authors:  Christina Gavegnano; Mervi A Detorio; Leda Bassit; Selwyn J Hurwitz; Thomas W North; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2012-12-21       Impact factor: 5.191

10.  Long-term AZT exposure alters the metabolic capacity of cultured human lymphoblastoid cells.

Authors:  Ofelia A Olivero; Irma L Vazquez; Catherine C Cooch; Jessica Ming; Emily Keller; Mia Yu; Jennifer P Borojerdi; Hannan M Braun; Edward McKee; Miriam C Poirier
Journal:  Toxicol Sci       Date:  2010-01-27       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.